Retrophin INC (RTRX) Holder Perceptive Advisors LLC Raised Its Stake by $14.36 Million as Stock Price Rose

Retrophin, Inc. (NASDAQ:RTRX) LogoInvestors sentiment decreased to 1.53 in 2019 Q2. Its down 0.10, from 1.63 in 2019Q1. It dropped, as 17 investors sold RTRX shares while 28 reduced holdings. 20 funds opened positions while 49 raised stakes. 43.81 million shares or 6.39% more from 41.18 million shares in 2019Q1 were reported. Millennium Mgmt Lc invested 0.06% in Retrophin, Inc. (NASDAQ:RTRX). Dimensional Fund Advsr Limited Partnership has 0.01% invested in Retrophin, Inc. (NASDAQ:RTRX) for 1.24M shares. Financial Bank Of Montreal Can holds 0% in Retrophin, Inc. (NASDAQ:RTRX) or 159,613 shares. Envestnet Asset, Illinois-based fund reported 18,698 shares. Palisade Capital Limited Nj holds 0.01% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX) for 11,502 shares. Panagora Asset Management Inc reported 454,192 shares stake. Tudor Investment Et Al reported 61,116 shares. Susquehanna Gp Ltd Liability Partnership invested 0% in Retrophin, Inc. (NASDAQ:RTRX). Hudson Bay Management LP holds 0.03% or 56,779 shares. Prudential Fincl holds 0.01% or 253,099 shares. Ameriprise holds 101,833 shares. Wolverine Asset Mgmt Llc stated it has 14,661 shares or 0% of all its holdings. Jpmorgan Chase & has invested 0% in Retrophin, Inc. (NASDAQ:RTRX). Virginia Retirement System Et Al holds 0.01% in Retrophin, Inc. (NASDAQ:RTRX) or 23,100 shares. Moreover, Spark Investment Mgmt Limited Company has 0.2% invested in Retrophin, Inc. (NASDAQ:RTRX) for 146,100 shares.

Perceptive Advisors Llc increased its stake in Retrophin Inc (RTRX) by 23.5% based on its latest 2019Q2 regulatory filing with the SEC. Perceptive Advisors Llc bought 717,875 shares as the company’s stock rose 4.05% . The hedge fund held 3.77M shares of the health care company at the end of 2019Q2, valued at $75.79 million, up from 3.05 million at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Retrophin Inc for a number of months, seems to be bullish on the $523.18 million market cap company. The stock increased 3.84% or $0.45 during the last trading session, reaching $12.18. About 568,562 shares traded. Retrophin, Inc. (NASDAQ:RTRX) has declined 26.70% since September 13, 2018 and is downtrending. It has underperformed by 26.70% the S&P500.

Perceptive Advisors Llc, which manages about $2.09B and $4.36B US Long portfolio, decreased its stake in Axonics Modulation Technologies Inc by 400,254 shares to 285,502 shares, valued at $11.70M in 2019Q2, according to the filing. It also reduced its holding in Rhythm Pharmaceuticals Inc by 240,000 shares in the quarter, leaving it with 262,970 shares, and cut its stake in Merit Medical Systems Inc (NASDAQ:MMSI).

More notable recent Retrophin, Inc. (NASDAQ:RTRX) news were published by: Globenewswire.com which released: “Retrophin to Present at Upcoming Investor Conferences – GlobeNewswire” on May 30, 2019, also Globenewswire.com with their article: “Retrophin to Report First Quarter 2019 Financial Results – GlobeNewswire” published on April 23, 2019, Benzinga.com published: “Mid-Day Market Update: Cato Rises After Q2 Results; Retrophin Shares Plunge – Benzinga” on August 22, 2019. More interesting news about Retrophin, Inc. (NASDAQ:RTRX) were released by: Nasdaq.com and their article: “Retrophin (RTRX) Reports Q2 Loss, Tops Revenue Estimates – Nasdaq” published on August 06, 2019 as well as Seekingalpha.com‘s news article titled: “Retrophin’s fosmetpantotenate flunks late-stage study in rare neurodegenerative disorder; shares down 25% premarket – Seeking Alpha” with publication date: August 22, 2019.

Retrophin, Inc. (NASDAQ:RTRX) Ratings Coverage

Among 4 analysts covering Retrophin (NASDAQ:RTRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Retrophin has $36 highest and $2000 lowest target. $27.25’s average target is 123.73% above currents $12.18 stock price. Retrophin had 7 analyst reports since April 5, 2019 according to SRatingsIntel. On Friday, August 23 the stock rating was maintained by BMO Capital Markets with “Outperform”. On Friday, August 23 the stock rating was maintained by Barclays Capital with “Overweight”. The rating was maintained by Canaccord Genuity on Friday, August 23 with “Buy”. Nomura maintained it with “Buy” rating and $3300 target in Friday, August 23 report.

Retrophin, Inc. (NASDAQ:RTRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.